Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
June 09 2021 - 4:15PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
William T. Andrews, M.D., F.A.C.P., will join the company as Chief
Medical Officer (CMO), effective July 1, 2021.
"Will brings an impressive combination of medical, clinical,
regulatory and corporate development skills, complemented by deep
commercial experience he gained launching seven products throughout
his career,” said Michael Clayman, MD, President and Chief
Executive Officer of Flexion Therapeutics. “He will play
an integral role in building and strengthening our organization,
and we could not be more excited to welcome him to our senior
management team.”
"I have been tremendously impressed by the caliber of the people
and the programs at Flexion, and I am delighted to join the company
at this exciting time in its growth and evolution,” said Dr.
Andrews. “I look forward to working closely with the team as we
prepare to investigate ZILRETTA® for the treatment of shoulder
osteoarthritis and as we advance our pipeline of potentially
transformative investigational drug candidates.”
Dr. Andrews has more than 20 years of experience in the
biopharmaceutical industry, most recently serving as CMO at Akcea
Therapeutics (acquired by Ionis Pharmaceuticals). Prior to Akcea,
Dr. Andrews served as CMO for Acer Therapeutics, a
biopharmaceutical company focused on the development of therapies
for rare and severe diseases. He previously held senior leadership
positions and roles of increasing responsibility at Aegerion
Pharmaceuticals, Santhera Pharmaceuticals, Sepracor, and
ClinQuest.
Dr. Andrews earned his B.A. in Biology from Harvard University
and his M.D. from Yale University School of Medicine. Before
joining industry, he practiced medicine in the Boston area for
seven years as a board-certified internist and an attending
physician at Brigham and Women’s Hospital and was on the clinical
faculty at Harvard Medical School.
Indication and Select Important Safety Information for
ZILRETTA (triamcinolone acetonide extended-release
injectable suspension)
Indication: ZILRETTA is indicated as an
intra-articular injection for the management of osteoarthritis pain
of the knee.
Limitation of Use: The efficacy and safety of repeat
administration of ZILRETTA have not been demonstrated.
Contraindication: ZILRETTA is
contraindicated in patients who are hypersensitive to triamcinolone
acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
-
Intra-articular Use Only: ZILRETTA has not
been evaluated and should not be administered by epidural,
intrathecal, intravenous, intraocular, intramuscular, intradermal,
or subcutaneous routes. ZILRETTA should not be considered safe for
epidural or intrathecal administration.
- Serious
Neurologic Adverse Reactions with Epidural and Intrathecal
Administration: Serious neurologic events have been
reported following epidural or intrathecal corticosteroid
administration. Corticosteroids are not approved for this use.
-
Hypersensitivity reactions: Serious reactions
have been reported with triamcinolone acetonide injection.
Institute appropriate care if an anaphylactic reaction occurs.
- Joint
infection and damage: A marked increase in joint
pain, joint swelling, restricted motion, fever and malaise may
suggest septic arthritis. If this occurs, conduct appropriate
evaluation and if confirmed, institute appropriate antimicrobial
treatment.
Adverse Reactions: The most commonly
reported adverse reactions (incidence ≥1%) in clinical studies
included sinusitis, cough, and contusions.
Please
see ZilrettaLabel.com for
full Prescribing Information.
About ZILRETTAOn October 6, 2017, ZILRETTA was
approved by the U.S. FDA as the first and only extended-release
intra-articular therapy for patients confronting
osteoarthritis-related knee pain. ZILRETTA employs proprietary
microsphere technology combining triamcinolone acetonide — a
commonly administered, short-acting corticosteroid — with a poly
lactic-co-glycolic acid (PLGA) matrix to provide extended pain
relief. The pivotal Phase 3 trial on which the approval of ZILRETTA
was based showed that ZILRETTA significantly reduced OA knee pain
for 12 weeks, with some people experiencing pain relief through
Week 16. Learn more at www.zilretta.com.
About Flexion TherapeuticsFlexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of people with musculoskeletal
conditions, beginning with osteoarthritis, the most common form of
arthritis. The Company's core values are focus, ingenuity,
tenacity, transparency and fun. Please
visit flexiontherapeutics.com.
Forward-Looking Statements This press release
contains forward-looking statements that are based on the current
expectations and beliefs of Flexion. Statements in this press
release regarding matters that are not historical facts, including,
but not limited to, statements relating to the future of Flexion;
future contributions of Dr. Andrews; and plans with respect to
clinical trials and development of Flexion’s pipeline, are forward
looking statements. These forward-looking statements are based on
management’s expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include, without limitation; risks related to
clinical trials, including potential delays, safety issues, or
negative results; the fact that future results may not be
consistent with preliminary results or results from prior studies
or trials; and other risks and uncertainties described in our
filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors”
in our Annual Report on Form 10-K for the year
ended December 31, 2020, filed with
the SEC on March 10, 2021, and subsequent
filings with the SEC. The forward-looking statements in this
press release speak only as of the date of this press release, and
we undertake no obligation to update or revise any of the
statements. We caution investors not to place considerable reliance
on the forward-looking statements contained in this press
release.
Contact:
Scott YoungVice President, Corporate Communications &
Investor RelationsT: 781-305-7194syoung@flexiontherapeutics.com
Julie DownsAssociate Director, Corporate Communications &
Investor RelationsT: 781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024